KALA

Kala Bio

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

29

Business Summary

Kala Bio is a biotechnology company focused on developing and commercializing therapies for eye diseases. The company works on innovative treatments aimed at addressing unmet medical needs in ophthalmology.

 


Analyze KALA on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$349

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

-

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$5.64

Next Year EPS Growth Estimate

-$0.53

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

413.60%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

-

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze KALA on TradingView

Gainseekers Quantitative Analysis

Summary

Kala Bio is a Nasdaq-listed biotechnology company with a market capitalization of $349 million and negative earnings of -$5.64 per share. The company is expected to improve earnings to -$0.53 per share next year, indicating a projected reduction in losses. Despite a very high reported return on equity of 413.60%, institutional ownership is low at 0.80%, and the stock carries a consensus rating of 3.

AI Exposure / Tech Reliance

As a biotechnology company in the healthcare sector, Kala Bio’s operations are primarily driven by scientific research and drug development rather than artificial intelligence infrastructure. Any AI exposure is likely limited to research and development processes rather than core revenue generation.

The Bull Case

The projected improvement in EPS from -$5.64 to -$0.53 suggests meaningful progress toward narrowing losses over the next year. A market cap of $349 million combined with a moderate short interest of 2.50% of float may indicate room for upside if clinical or financial milestones are achieved.

The Bear Case

The company remains unprofitable with negative earnings, and key valuation metrics such as P/E and Price/Sales are not available due to ongoing losses. Very low institutional ownership at 0.80% may signal limited support from large investors, potentially increasing volatility.

Market Sentiment & Smart Money

Short Interest %

2.50%

Analyst Consensus

3

Average Analyst Price Target

-

Institutional Ownership %

0.80%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.